[ad_1]

BACKGROUND:

A 239-query cross-sectional survey was sent out through e-mail in January 2017 to collect extensive info on cannabis use from Canadian healthcare cannabis patients registered with a federally authorized licensed cannabis producer, resulting in 2032 comprehensive surveys.

Solutions:

The survey gathered detailed demographic information and extensive info on patient patterns of healthcare cannabis use, like concerns assessing the self-reported effect of cannabis on the use of prescription drugs, illicit substances, alcohol, and tobacco.

Outcomes:

Participants have been 62.six% male (n = 1271) and 91% Caucasian (n = 1839). The imply age was 40 years old, and discomfort and mental wellness situations accounted for 83.7% of all respondents (n = 1700). Then, 74.six% of respondents reported daily cannabis use (n = 1515) and imply quantity employed per day was 1.5 g. The most usually cited substitution was for prescription drugs (69.1%, n = 953), followed by alcohol (44.five%, n = 515), tobacco (31.1%, n = 406), and illicit substances (26.six%, n = 136). Opioid medicines accounted for 35.three% of all prescription drug substitution (n = 610), followed by antidepressants (21.five%, n = 371). Of the 610 mentions of certain opioid medicines, individuals report total cessation of use of 59.three% (n = 362).

CONCLUSIONS:

This study delivers a distinctive point of view by focusing on the use of a standardized, government-regulated supply of healthcare cannabis by individuals registered in Canada’s federal healthcare cannabis program. The findings present a granular view of patient patterns of healthcare cannabis use, and the subsequent self-reported impacts on the use of opioids, alcohol, and other substances, adding to a increasing physique of academic study suggesting that elevated regulated access to healthcare and recreational cannabis can outcome in a reduction in the use of and subsequent harms related with opioids, alcohol, tobacco, and other substances.

[ad_2]